Drug Trial Radar · NCT07581002
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
660
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Jun 2032
Study completion Jun 2032
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood cell production. This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA) in adult participants with AML ineligible to receive intensive chemotherapy. Pivekimab sunirine is a drug being evaluated in the treatment of AML.This is a Phase 2/Phase 3, study of PVEK. Phase 2 is open-label and randomized. Phase 3 is double-blind, randomized. Phase 2 and Phase 3 studies test potential new treatments in patients with a condition or disease. Open-label means that both patients and study doctors know which study treatment is given to patients in Phase 2 of the study. Double-blind means that neither the patients nor the study doctors know who is given which study treatment in Phase 3 of the study. Approximately 660 adult participants will be enrolled in 180 sites worldwide. In Phase 2 of the study, patients will be randomized to receive PVEK + VEN + AZA or standard of care treatment with VEN + AZA. In Phase 3, patients will be randomized to receive PVEK + VEN + AZA or a matching-placebo for PVEK plus VEN + AZA. PVEK is given as an infusion into the vein, AZA is given as an injection under your skin (subcutaneous) or as an infusion into the vein (intravenous) (depending on country where patient enrolls), and VEN is a tablet given by mouth. The total study duration is approximately 71 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Conditions
- Acute Myeloid Leukemia
Interventions
Pivekimab SunirineDrug
Intravenous
VenetoclaxDrug
Orally
AzacitidineDrug
Intravenous Or Subcutaneous
Matching Placebo for PVEKDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Complete remission (CR)Time frame: Up to Approximately 71 Months
- Phase 3: Complete remission (CR)Time frame: Up to Approximately 71 Months
- Phase 3: Overall Survival (OS)Time frame: Up to Approximately 71 Months
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 71 months
Locations
40 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 279568
Duarte, California · Recruiting
Moffitt Cancer Center /ID# 279192
Tampa, Florida · Recruiting
Winship Cancer Institute of Emory University /ID# 279006
Atlanta, Georgia · Recruiting
Washington University /ID# 280295
St Louis, Missouri · Recruiting
Montefiore Medical Center - Moses Campus /ID# 279399
The Bronx, New York · Recruiting
Penn Medicine University of Pennsylvania Health System /ID# 279382
Philadelphia, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center /ID# 279402
Houston, Texas · Recruiting
Medizinische Universitaet Wien /ID# 278825
Vienna, Austria · Recruiting
Universitaetsklinikum St. Poelten /ID# 278835
Sankt Pölten, Lower Austria, Austria · Recruiting
Hanusch-Krankenhaus /ID# 279467
Vienna, State of Vienna, Austria · Recruiting
Medizinische Universitaet Graz /ID# 278830
Graz, Styria, Austria · Recruiting
Ordensklinikum Linz Elisabethinen /ID# 278824
Linz, Upper Austria, Austria · Recruiting
Hopital Saint-Louis /ID# 279032
Paris, France · Recruiting
Chu De Nice-Hopital Larchet II /ID# 278998
Nice, Alpes-Maritimes, France · Recruiting
Institut Paoli-Calmettes /ID# 279015
Marseille, Bouches-du-Rhone, France · Recruiting
Centre Hospitalier Universitaire de Bordeaux /ID# 279001
Pessac, New Aquitaine, France · Recruiting
Centre Hospitalier Universitaire D'Angers /ID# 280390
Angers, Pays de la Loire Region, France · Recruiting
CHU Amiens-Picardie Site Sud /ID# 280716
Amiens, Somme, France · Recruiting
Rambam Health Care Campus- Haifa /ID# 278719
Haifa, Israel · Recruiting
Shaare Zedek Medical Center /ID# 278712
Jerusalem, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 278866
Jerusalem, Israel · Recruiting
Rabin Medical Center /ID# 278714
Petah Tikva, Central District, Israel · Recruiting
Tel Aviv Sourasky Medical Center /ID# 278717
Tel Aviv, Tel Aviv, Israel · Recruiting
Seoul National University Bundang Hospital /ID# 279634
Seongnam-si, Gyeonggido, South Korea · Recruiting
Seoul National University Hospital /ID# 279396
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Yonsei University Health System - Severance Hospital /ID# 279933
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Asan Medical Center /ID# 279395
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Samsung Medical Center /ID# 279397
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Hospital General Universitario Gregorio Maranon /ID# 279479
Madrid, Spain · Recruiting
Hospital MD Anderson Cancer Center Madrid /ID# 279480
Madrid, Spain · Recruiting
Hospital Universitario Ramon y Cajal /ID# 279638
Madrid, Spain · Recruiting
Hospital Clinico Universitario de Valencia /ID# 279635
Valencia, Spain · Recruiting
Hospital Universitario Puerta De Hierro /ID# 279660
Majadahonda, Madrid, Spain · Recruiting
Clinica Universidad de Navarra - Pamplona /ID# 279516
Pamplona, Navarre, Spain · Recruiting
Hospital Universitario Virgen del Rocio /ID# 279471
Seville, Sevilla, Spain · Recruiting
China Medical University Hospital /ID# 279261
Taichung, Taiwan · Recruiting
Taichung Veterans General Hospital /ID# 279296
Taichung, Taiwan · Recruiting
National Taiwan University Hospital /ID# 279289
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital /ID# 281480
Taipei, Taiwan · Recruiting
Linkou Chang Gung Memorial Hospital /ID# 279294
Taoyuan City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.